Prostate Specific Membrane Antigen (D7I8E) XP® Rabbit mAb #12815
- WB
- IHC
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 100 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IHC-Immunohistochemistry
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunohistochemistry (Paraffin) | 1:50 - 1:200 |
Storage
For a carrier free (BSA and azide free) version of this product see product #92728.
Protocol
Specificity / Sensitivity
Prostate Specific Membrane Antigen (D7I8E) XP® Rabbit mAb recognizes endogenous levels of total prostate specific membrane antigen. An SDS resistant dimer at approximately 200 kDa can be detected depending on sample preparation conditions.
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues in the extracellular domain of human prostate specific membrane antigen protein.
Background
Prostate specific membrane antigen (PSMA, also known as FOLH1), a type II transmembrane protein of the M28 family, has both folate hydrolase and N-acetylated-alpha-linked acidic dipeptidase activity. PSMA was originally identified in the LNCaP cell line, which was derived from a prostate adenocarcinoma lymph node metastasis (1,2). PSMA is an established prostate cancer marker (3); however, it is expressed in other tissues, including kidney, liver, and urinary bladder (4), and it is associated with tumor neovasculature (5) as well. Research studies suggest that PSMA is both a potential diagnostic readout and therapeutic target (6-8).
- Horoszewicz, J.S. et al. (1987) Anticancer Res 7, 927-35.
- Israeli, R.S. et al. (1993) Cancer Res 53, 227-30.
- Ben Jemaa, A. et al. (2010) J Exp Clin Cancer Res 29, 171.
- Kinoshita, Y. et al. (2006) World J Surg 30, 628-36.
- Chang, S.S. et al. (1999) Mol Urol 3, 313-320.
- Mease, R.C. et al. (2013) Curr Top Med Chem 13, 951-62.
- Frigerio, B. et al. (2013) Eur J Cancer 49, 2223-32.
- Denmeade, S.R. et al. (2012) Sci Transl Med 4, 140ra86.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.